AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability

Takahiro Mikami, head of immunology AbbVie plans to further expand indications for its anti-TNFα antibody drug Humira (adalimumab), which currently has nine indications. “We’ll continue looking for opportunities to expand Humira’s indications for diseases involving tumor necrosis factor α (TNFα)...read more